Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents

Journal of the National Cancer Institute

Volumn 96, Issue 21, 2004, Pages 1593-1603

  Studeny, Matus ^a   Marini, Frank C ^a   Dembinski, Jennifer L ^a   Zompetta, Claudia ^a   Cabreira Hansen, Maria ^a   Bekele, Benjamin Nebiyou ^a   Champlin, Richard E ^a   Andreef, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BETA INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER SURVIVAL; CARCINOMA CELL; CELL PROLIFERATION; COCULTURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TARGETING; EXPRESSION VECTOR; FLOW CYTOMETRY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG METASTASIS; MELANOMA CELL; MESENCHYME CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; STEM CELL; STROMA; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; ADENOVIRUS; ANIMAL; BREAST TUMOR; CELL CULTURE; CELL DIVISION; DRUG EFFECT; EXPERIMENTAL MELANOMA; GENE VECTOR; GENETIC TRANSFECTION; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MELANOMA; MESENCHYMAL STEM CELL; METASTASIS; MOUSE MUTANT; SURVIVAL; XENOGRAFT;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL DIVISION; FLOW CYTOMETRY; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAVENOUS; INTERFERON-BETA; LUNG NEOPLASMS; MELANOMA; MELANOMA, EXPERIMENTAL; MESENCHYMAL STEM CELLS; MICE; MICE, SCID; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 7944220831     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djh299     Document Type: Article

References (42)

1. Wong VL, Rieman DJ, Aronson L, Dalton BJ, Greig R, Anzano MA. Growth-inhibitory activity of interferon-beta against human colorectal carcinoma cell lines. Int J Cancer 1989;43:526-30.
2. Johns TG, Mackay IR, Callister KA, Hertzog PJ, Devenish RJ, Linnane AW. Antiproliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta. J Natl Cancer Inst 1992;84:1185-90.
3. Chawla-Sarkar M, Leaman DW, Borden EC. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res 2001;7:1821-31.
4. Lokshin A, Mayotte JE, Levitt ML. Mechanism of interferon beta-induced squamous differentiation and programmed cell death in human non-small-cell lung cancer cell lines. J Natl Cancer Inst 1995;87:206-12.
5. Zhang H, Koty PP, Mayotte J, Levitt ML. Induction of multiple programmed cell death pathways by IFN-beta in human non-small-cell lung cancer cell lines. Exp Cell Res 1999;247:133-41.
6. Bradley JD, Scott CB, Paris KJ Demas WF, Machtay M, Komaki R, et al. A phase III comparison of radiation therapy with or without recombinant beta-interferon for poor-risk patients with locally advanced non-small-cell lung cancer (RTOG 93-04). Int J Radiat Oncol Biol Phys 2002;52:1173-9.
7. Kowalzick L, Weyer U, Lange P, Breitbart EW. Systemic therapy of advanced metastatic malignant melanoma with a combination of fibroblast interferon-beta and recombinant interferon-gamma. Dermatologica 1990; 181:298-303.
8. Schiller JH, Storer B, Bittner G, Willson JK, Borden EC. Phase II trial of a combination of interferon-beta ser and interferon-gamma in patients with advanced malignant melanoma. J Interferon Res 1988;8:581-9.
9. Tester WJ, Kim KM, Krigel RL, Bonomi PD, Glick JH, Asbury RF, et al. A randomized phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586). Lung Cancer 1999;5:199-206.
10. Von Hoff DD, Metch B, Lucas JG, Balcerzak SP, Grunberg SM, Rivkin SE. Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study. J Interferon Res 1990;10:531-4.
11. Buchwalder PA, Buclin T, Trinchard I, Munafo A, Biollaz J. Pharmacokinetics and pharmacodynamics of IFN-beta 1a in healthy volunteers. J Interferon Cytokine Res 2000;20:857-66.
12. Salmon P, Le Cotonnec JY, Galazka A, Abdul-Ahad A, Darragh A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. J Interferon Cytokine Res 1996;16:759-64.
13. Einhorn S, Grander D. Why do so many cancer patients fail to respond to interferon therapy? J Interferon Cytokine Res 1996;16:275-81.
14. Bocci V, Carraro F, Naldini A, Borrelli E, Biagi G, Gotti G, et al, Interferon levels in human pulmonary tumors are lower than plasma levels. J Biol Regul Homeost Agents 1990;4:153-6.
15. Johns TG, Kerry JA, Veitch BA, Mackay IR, Tutton PJ, Tymms M, et al. Pharmacokinetics, tissue distribution, and cell localization of [35S]methionine-labeled recombinant human and marine alpha interferons in mice. Cancer Res 1990;50:4718-23.
16. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002;62:3603-8.
17. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997;276:71-4.
18. Pittenger ME, Mackay AM, Beck SC Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999:284:143-7.
19. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999;5:309-13.
20. Liechty KW, Mackenzie TC, Shaaban AF, Radu A, Moseley AM, Deans R, et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 2000;6:1282-6.
21. Weissman IL. Stem cells: units of development, units of regeneration, and units in evolution. Cell 2000;100:157-68.
22. Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM. Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 2002;109:337-46.
23. Wu GD, Nolta JA, Jin YS, Baar ML, Yu H, Starnes VA, et al. Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation 2003;75:679-85.
24. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
25. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-9.
26. Hasebe T, Sasaki S, Sugitoh M, Ono M, Saitoh N, Ochiai A. Highly proliferative intratumoral fibroblasts and a high proliferative microvessel index are significant predictors of tumor metastasis in T3 ulcerative-type colorectal cancer. Hum Pathol 2001;32:401-9.
27. Kuniyasu H, Abbruzzese JL, Cleary KR, Fidler IJ. Induction of ductal and stromal hyperplasia by basic fibroblast growth factor produced by human pancreatic carcinoma. Int J Oncol 2001;19:681-5.
28. Qin XQ, Beckham C, Brown JL, Lukashev M, Barsoum J. Human and mouse IFN-beta gene therapy exhibits different anti-tumor mechanisms in mouse models. Mol Ther 2001;4:356-64.
29. Lee K, Majumdar MK, Buyaner D, Hendricks JK, Pittenger MF, Mosca JD. Human mesenchymal stem cells maintain transgene expression during expansion and differentiation. Mol Ther 2001;3:857-66.
30. Bielenberg DR, McCarty MF, Bucana CD, Yuspa SH, Morgan D, Arbeit JM, et al. Expression of interferon-beta is associated with growth arrest of murine and human epidermal cells. J Invest Dermatol 1999;112:802-9.
31. Hertzog PJ, Hwang SY, Kola I. Role of interferons in the regulation of cell proliferation, differentiation, and development. Mol Reprod Dev 1994;39:226-32.
32. Koc ON, Peters C, Aubourg P, Raghavan S, Dyhouse S, DeGasperi R, et al. Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. Exp Hematol 1999;27:1675-81.
33. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzales XR, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41-9.
34. Clemens MJ, McNurlan MA. Regulation of cell proliferation and differentiation by interferons. Biochem J 1985:226:345-60.
35. Clifford JL, Walch E, Yang X, Xu X, Alberts DS, Clayman GL, et al. Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis. Clin Cancer Res 2002;8:2067-72.
36. Gerfaux J, Sergiescu D, Fournier JG, Pochart F, Joret AM, Chany C. Presence of a constitutive paracrine beta-interferon in v-mos-bearing nonmalignant reverted cells. Cancer Res 1989;49:1241-6.
37. Sergiescu D, Gerfaux J, Joret AM, Chany C. Persistent expression of v-mos oncogene in transformed cells that revert to nonmalignancy after prolonged treatment with interferon. Proc Natl Acad Sci U S A 1986;83:5764-8.
38. Barber GN. The interferons and cell death: guardians of the cell or accomplices of apoptosis? Semin Cancer Biol 2000;10:103-11.
39. Bielenberg DR, Bucana CD, Sanchez R, Mulliken JB, Folkman J, Fidler IJ. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta. Int J Oncol 1999;14:401-8.
40. Kuniyasu H, Yasui W, Shinohara H, Yano S, Ellis LM, Wilson MR, et al. Induction of angiogenesis by hyperplastic colonic mucosa adjacent to colon cancer. Am J Pathol 2000;157:1523-35.
41. Hohlbaum AM, Moe S, Marshak-Rothstein A. Opposing effects of transmembrane and soluble Fas ligand expression on inflammation and tumor cell survival. J Exp Med 2000:191:1209-20.
42. Eder JP Jr, Supko JG, Clark JW, Puchalski TA, Garcia-Carbonero R, Ryan DP, et al. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J Clin Oncol 2002:20:3772-84.